Molecular analysis of V617F mutation in Janus kinase 2 gene of breast cancer patients.
Allele-specific PCR
Breast cancer
JAK2
Sanger’s sequencing
V617F mutation
Journal
Saudi journal of biological sciences
ISSN: 1319-562X
Titre abrégé: Saudi J Biol Sci
Pays: Saudi Arabia
ID NLM: 101543796
Informations de publication
Date de publication:
Sep 2019
Sep 2019
Historique:
received:
27
05
2019
revised:
31
07
2019
accepted:
01
08
2019
entrez:
14
9
2019
pubmed:
14
9
2019
medline:
14
9
2019
Statut:
ppublish
Résumé
Breast cancer is a multifactorial disease with the highest frequency in females. Genetic and environmental factors can cause mutation in several genes like tyrosine kinase, JAK2 gene which may initiate cancer. Molecular analysis of mutations in the Blood was collected from seventy breast cancer patients after their consent. The questionnaire included risk factors, age group, locality, number of children, tumor type, family history, time of initial diagnosis, no of cycles/month, water conditions and exposure to radiations. Molecular analysis were carried out from genomic DNA using Sanger sequencing and allele-specific PCR to check the V617F point mutation. The breast cancer risk factors includes unfiltered water (68.57%), urban (58.57%), menopause (55.71%), family history of cancer (18.57%), tumor grades (II, 37.14% and III, 35.71%), consanguineous marriages (44.28%) and having more than 3-4 children (45.71%). Prevalence of breast cancer was higher after the age of 35 and maximum at 35-50. In allele-specific PCR of 70 patients, 25 patients were wild type (229 bp), 25 patients were with partially deleted gene (200 bp), and 20 patient had shown no or less than 40 bp size fragments. In Sanger's sequencing of 70 BC cases, 18% were found to be positive for V617F point mutation, including 6 homozygous (T/T) and 7 heterozygous (G/T) mutations at nucleotide position 1849 in exon 14 of the Environmental and clinical risk factors were associated with breast cancer which can be overcome by improving awareness of associated risks, health facilities and reducing stress.
Sections du résumé
BACKGROUND
BACKGROUND
Breast cancer is a multifactorial disease with the highest frequency in females. Genetic and environmental factors can cause mutation in several genes like tyrosine kinase, JAK2 gene which may initiate cancer. Molecular analysis of mutations in the
METHODS
METHODS
Blood was collected from seventy breast cancer patients after their consent. The questionnaire included risk factors, age group, locality, number of children, tumor type, family history, time of initial diagnosis, no of cycles/month, water conditions and exposure to radiations. Molecular analysis were carried out from genomic DNA using Sanger sequencing and allele-specific PCR to check the V617F point mutation.
RESULTS
RESULTS
The breast cancer risk factors includes unfiltered water (68.57%), urban (58.57%), menopause (55.71%), family history of cancer (18.57%), tumor grades (II, 37.14% and III, 35.71%), consanguineous marriages (44.28%) and having more than 3-4 children (45.71%). Prevalence of breast cancer was higher after the age of 35 and maximum at 35-50. In allele-specific PCR of 70 patients, 25 patients were wild type (229 bp), 25 patients were with partially deleted gene (200 bp), and 20 patient had shown no or less than 40 bp size fragments. In Sanger's sequencing of 70 BC cases, 18% were found to be positive for V617F point mutation, including 6 homozygous (T/T) and 7 heterozygous (G/T) mutations at nucleotide position 1849 in exon 14 of the
CONCLUSIONS
CONCLUSIONS
Environmental and clinical risk factors were associated with breast cancer which can be overcome by improving awareness of associated risks, health facilities and reducing stress.
Identifiants
pubmed: 31516339
doi: 10.1016/j.sjbs.2019.08.002
pii: S1319-562X(19)30134-2
pmc: PMC6733781
doi:
Types de publication
Journal Article
Langues
eng
Pagination
1123-1128Déclaration de conflit d'intérêts
The authors declare that there is no conflict of interest.
Références
J Clin Oncol. 1999 Mar;17(3):870-9
pubmed: 10071278
Blood. 2005 Sep 15;106(6):2162-8
pubmed: 15920007
Cardiovasc Hematol Agents Med Chem. 2007 Jul;5(3):198-203
pubmed: 17630945
BMC Cancer. 2007 Dec 18;7:226
pubmed: 18088415
Cancer Lett. 2009 Oct 18;284(1):7-14
pubmed: 19269737
Mol Cancer Ther. 2010 Jul;9(7):1945-55
pubmed: 20587663
Curr Med Chem. 2011;18(30):4659-73
pubmed: 21864276
Nat Med. 2012 Feb 12;18(3):382-4
pubmed: 22327622
Nat Struct Mol Biol. 2012 Aug;19(8):754-9
pubmed: 22820988
Int J Hematol. 2014 Jan;99(1):87-90
pubmed: 24293258
Pak J Med Sci. 2014 Jan;30(1):185-8
pubmed: 24639858
PLoS One. 2014 May 07;9(5):e95993
pubmed: 24804649
Blood. 2015 May 28;125(22):3388-92
pubmed: 25824690
Alcohol Alcohol. 2016 May;51(3):315-30
pubmed: 26400678
Cancer Biother Radiopharm. 2016 Aug;31(6):199-208
pubmed: 27403569
Hematol Oncol Stem Cell Ther. 2017 Mar;10(1):44-45
pubmed: 27614229
Breast. 2017 Feb;31:167-172
pubmed: 27871024
Tumour Biol. 2017 Jun;39(6):1010428317711140
pubmed: 28639892
Genome Med. 2017 Oct 30;9(1):89
pubmed: 29082853
PLoS One. 2018 Apr 11;13(4):e0194098
pubmed: 29641532
Indian J Pathol Microbiol. 2018 Jul-Sep;61(3):371-374
pubmed: 30004057
Sci Transl Med. 2019 Jan 23;11(476):
pubmed: 30674656
J Investig Med High Impact Case Rep. 2019 Jan-Dec;7:2324709619832322
pubmed: 30803277
J Am Coll Surg. 1994 Mar;178(3):213-9
pubmed: 8149010
N Engl J Med. 1994 Jan 13;330(2):81-7
pubmed: 8259187
Epidemiol Rev. 1993;15(1):7-16
pubmed: 8405214